Please be aware of suspicious e-mails purporting to be from our company's employees and directors

Strategic Business Partnership between ROHTO MediLuxe Europe and EMA AESTHETICS

ROHTO Pharmaceutical Co., Ltd. Investing to Develop Novel Solution for Urinary Incontinence Symptoms, Venturing into New Values, Products, and Businesses in the Healthcare Sector.

Establishment of Sustainability Targets 2030 (environmental and social axis)

Fujita Gakuen and ROHTO Pharmaceutical Co., Ltd. established a joint venture and entered the real-world data business.

Announcement: Commencement of Phase II Clinical Trials for Janus Kinase Inhibitor "ROH-201" in Japan

Notice of Commencement of Domestic Phase I Clinical Trial for Ophthalmic Therapeutic Agent "ROH-202"

Announcement of Collaborative Research Agreement for Creating a Solution to Predict Systemic Diseases from Eye Health Information

Announcement of Commencement of Domestic Phase III Clinical Trial for Cytomegalovirus Endotheliitis

We evaluated the performance of rapid test kits for coronavirus (SARS-CoV-2) antigens using laboratory samples.